Sulfonylureas
Sulfonylureas | NWL guidelines |
Gliclazide | |
< 60 = Consider ↓ dose - ^hypo risk | < 30 = STOP
Glimepiride | |
< 60 = Consider ↓ dose - ^hypo risk | < 30 = STOP
| HbA1c reduction |
Weight change |
Hypo risk |
| 11-22mmols/mol (1-2%) |
2-3lb gain |
Moderate |
Patients newly diagnosed with T2DM: Retinal photocoagulation
| ARR |
NNT |
RRR |
| 2.7% |
37 |
26.2% |
"If 100 people take insulin or a sulphonylurea for 10 years, 2.7 will avoid the need for retinal photocoagulation compared to those not taking these drugs"
Patients newly diagnosed with T2DM: Non-fatal MI
| ARR |
NNT |
RRR |
| 1.7% |
60 |
18.7% |
"If 100 people take insulin or a sulphonylurea for 10 years, 1.7 will avoid a non-fatal MI compared to those not taking these drugs"
Patients newly diagnosed with T2DM:
Combined microvascular endpoints
| ARR |
NNT |
RRR |
| 2.4% |
42 |
22.5% |
"If 100 people take insulin or a sulphonylurea for 10 years, 2.4 will avoid a microvascular endpoint compared to those not taking these drugs"
Patients newly diagnosed with T2DM: Amputation
"A small but non-statistically significant reduction in the rate of amputation was observed with drug treatment"
Patients newly diagnosed with T2DM: Renal failure
"A small but non-statistically significant reduction the rates of renal failure was observed with drug treatment"
Patients newly diagnosed with T2DM: Blindness in 1 eye
"A small but non-statistically significant reduction the rates of blindness in 1 eye was observed with drug treatment"